About Orixha

Orixha’s Mission

Orixha’s mission statement is

« To save the lives of critical care patients through our unique liquid ventilation technology ».

This shared objective was the key impetus behind the creation of Orixha by its seven co-founders: A. Berdeaux MD PharmD, M. Kohlhauer DVM PhD, P. Micheau Eng PhD, M. Nadeau Eng PhD, F. Paublant MBA, R. Tissier DVM PhD, H. Walti, MD PhD,

This commitment was renewed in 2022 when the Orixha’s raison d’être (mission statement) was approved by all the shareholders and included in its corporate charters.

Since its foundation in 2018, several milestones and significant events occurred towards the realization of this shared goal.

2018

Creation of the company

2019

Worldwide license on TLV from Erganeo. i-Lab winner

2020

Prototype LV4C validated. i-Nov winner

2021

Seed round closing

Governance established

2022

Vent2Cool Design Freeze

Laureate EIC Accelerator for the LuncoLive projet

2023

Vent2Cool validated for clinical study

2024

4 million euros raised from the EIC Fund and Bpifrance

ORIXHA obtains French Health Authority approval to initiate its feasibility clinical study in Post Cardiac Arrest Syndrome

2025

Publication of the OverCool clinical trial protocol : Performance and Safety validation of Vent2Cool in Post Cardiac Arrest Syndrome

(L2B)² project for breathable liquid reprocessing is awarded 4 million euros grant by France 2030

The name “Orixha” is a symbol of this fruitful teamwork between Canadian and French researchers as well as their dedication to a faster and more efficient hypothermia solution as it means “cold breath” and is associated with the northern wind for the Huron people.